TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Abstract

PARP inhibition is an effective treatment for patients with MBC and g<i>PALB2</i> or s<i>BRCA1</i>/<i>2</i> mutations, significantly expanding the population of patients with breast cancer likely to benefit from PARPi beyond g<i>BRCA1</i>/<i>2</i> mutation carriers. These results emphasize the value of molecular characterization for treatment decisions in MBC.